EN3356 is an orally available and selective inhibitor of steroidal 17-alpha-hydroxylase/C17,20 cleavage enzyme (CYP17A1 or CYP17), a non-steroidal cleavage enzyme-selective compound with potential anti-androgenic and anti-tumor activity.

97%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

EN3356 (50, 100, 200 mg; oral; escalating doses; once a day) was well tolerated, and drug-related AEs were CTCAE Gr 1 and 2 incl. myalgia, anorexia, flushing, hot flashes, and presyncope. Excellent systemic exposure was observed at both 50 mg and 100 mg QD regimens (Cmax, Ctrough, and AUCτ at 100 mg QD were 3.5 uM, 1.8 uM, and 52 uM.h, respectively). The Phase 1 clinical study results to date show that EN3356 is safe and well tolerated at doses of up to 100 mg daily.[1]